Allogene Therapeutics Announces Patient Screening Underway For Pivotal Phase 2 ALPHA3 Trial At Rocky Mountain Cancer Centers, Astera Cancer Care, And Norton Cancer Institute; ALPHA3 To Offer CAR T As First Line Treatment At Community Cancer Centers,...
Allogene Therapeutics Announces Patient Screening Underway For Pivotal Phase 2 ALPHA3 Trial At Rocky Mountain Cancer Centers, Astera Cancer Care, And Norton Cancer Institute; ALPHA3 To Offer CAR T As First Line Treatment At Community Cancer Centers,...
Allogene Therapeutics宣佈，在Rocky Mountain Cancer Centers、Astera Cancer Care和Norton Cancer Institute進行了重要第二階段ALPHA3臨床試驗的患者篩選; ALPHA3將在社區癌症中心提供CAR T作爲一線治療...
Allogene Therapeutics Announces Patient Screening Underway For Pivotal Phase 2 ALPHA3 Trial At Rocky Mountain Cancer Centers, Astera Cancer Care, And Norton Cancer Institute; ALPHA3 To Offer CAR T As First Line Treatment At Community Cancer Centers, Aiming To Complete Enrollment By 1H 2026 And Potential BLA Submission In 2027
Allogene Therapeutics 宣佈正在洛基山癌症中心、Astera Cancer Care 和諾頓癌症研究所進行關鍵的 2 期 ALPHA3 試驗的患者篩查；ALPHA3 將在社區癌症中心提供 CAR T 作爲一線治療，目標在 2026 年上半年完成入組，並可能在 2027 年提交 BLA
- Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute; Astera Cancer Care, Part of the OneOncology Network; and Norton Cancer Institute
- ALPHA3 Will be the First Pivotal Trial to Offer CAR T as Part of First Line (1L) Treatment at Community Cancer Centers, Where 80% of Patients Receive Care
- ALPHA3 Expected to Complete Enrollment in 1H 2026; Potential BLA Submission in 2027
- 美國腫瘤網絡和莎拉·坎農研究所下屬的洛基山癌症中心、隸屬於OneOncology網絡的Astera Cancer Care和諾頓癌症研究所正在進行患者篩查
- ALPHA3 將是首項在社區癌症中心提供 CAR T 作爲一線 (1L) 治療一部分的關鍵試驗，80% 的患者將在該中心接受治療
- ALPHA3 預計將於 2026 年上半年完成註冊；可能在 2027 年提交 BLA